Dear colleagues and friends,
With the aging of the population, the incidence of heart valvular disease is increasing rapidly, which is a serious threat to human life and health.The percutaneous interventional therapy of cardiac valvular disease is becoming more and more mature, which opens a new era in the treatment of cardiac valvular disease.In recent years, China Valve (China Valve) interventional diagnosis and treatment work rapid development, has made remarkable achievements.
In order to promote the further development of China's valvular cause and promote international exchanges and cooperation in the interventional diagnosis and treatment of heart valvular diseases,Sponsored by the second hospital affiliated to zhejiang university school of medicine, zhejiang medical doctor association cardiovascular physician branch co-host, international conference on Structural Heart Disease CSI (Catheter Interventions in Congenital, Structural and Valvular Heart diseases) support the fifth "China Valve (Hangzhou) 2020" will be held in Hangzhou huanglong hotel on July 25.
Congress will be invited to the international top experts in the field of heart Valve in diagnosis and treatment, with Transcatheter Aortic Valve Replacement (Transcatheter Aortic Valve Replacement, TAVR) as the center, in combination with the field of the latest academic progress, through academic lectures, recorded cases, surgery broadcast (domestic and international), cases discussion, expert on road, simulator, operating a variety of forms such as, in preparation for conducting TAVR center provides systematic training, to have carried out preliminary TAVR center provide more chances of technology,To provide an experience exchange and cooperation platform for the experienced TAVR center, and ultimately benefit the majority of patients with heart valve disease.
We meet with you in hangzhou, enjoy the beautiful spring scenery of the west lake, promote the new technology majestic!